BR112012013582A2 - processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos - Google Patents

processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos

Info

Publication number
BR112012013582A2
BR112012013582A2 BR112012013582A BR112012013582A BR112012013582A2 BR 112012013582 A2 BR112012013582 A2 BR 112012013582A2 BR 112012013582 A BR112012013582 A BR 112012013582A BR 112012013582 A BR112012013582 A BR 112012013582A BR 112012013582 A2 BR112012013582 A2 BR 112012013582A2
Authority
BR
Brazil
Prior art keywords
production
synthesis
substituted indazole
compounds
intermediates useful
Prior art date
Application number
BR112012013582A
Other languages
English (en)
Inventor
Hossein Razavi
Jonathan Timothy Reeves
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112012013582A2 publication Critical patent/BR112012013582A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Abstract

processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos. a presente invenção refere-se a processos para preparação de compostos de f´romula (i): os compostos são úteis como intermediários para preparação de compostos de indazol e azaindazol substituídos.
BR112012013582A 2009-12-08 2010-12-01 processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos BR112012013582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08
PCT/US2010/058594 WO2011071730A1 (en) 2009-12-08 2010-12-01 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Publications (1)

Publication Number Publication Date
BR112012013582A2 true BR112012013582A2 (pt) 2016-07-05

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013582A BR112012013582A2 (pt) 2009-12-08 2010-12-01 processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos

Country Status (16)

Country Link
US (1) US20110137042A1 (pt)
EP (1) EP2509952A1 (pt)
JP (1) JP2013512954A (pt)
KR (1) KR20120101667A (pt)
CN (1) CN102596908A (pt)
AR (1) AR079324A1 (pt)
AU (1) AU2010328480A1 (pt)
BR (1) BR112012013582A2 (pt)
CA (1) CA2782384A1 (pt)
CL (1) CL2012001300A1 (pt)
EA (1) EA201200820A1 (pt)
IL (1) IL219274A0 (pt)
IN (1) IN2012DN05081A (pt)
MX (1) MX2012006524A (pt)
TW (1) TW201144282A (pt)
WO (1) WO2011071730A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
CA2778060A1 (en) 2009-10-21 2011-04-28 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2116863A1 (en) * 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU674240B2 (en) * 1993-06-25 1996-12-12 Ihara Chemical Industry Co. Ltd. Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof
JPH10509721A (ja) * 1994-12-06 1998-09-22 メルク シヤープ エンド ドーム リミテツド ５ｈｔ１レセプターアゴニストとしてのアゼチジン、ピロリジン及びピペリジン誘導体
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
KR20010031783A (ko) * 1997-11-04 2001-04-16 데이비드 존 우드 Ｐｄｅ4 억제제 중 인다졸에 의한 카테콜의 생등입체성치환을 기재로 하는 치료상 활성인 화합물
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6855715B1 (en) * 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
TW200406385A (en) * 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
JP4713465B2 (ja) * 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2007502307A (ja) * 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
DE602006003641D1 (de) * 2005-03-16 2008-12-24 Basf Se Biphenyl-n-(4-pyridyl) methylsulfonamide
HUE031979T2 (en) * 2005-05-17 2017-08-28 Sarcode Bioscience Inc Preparations and methods for treating eye disorders
AU2006287202B2 (en) * 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
JP2009513677A (ja) * 2005-10-25 2009-04-02 スミスクライン・ビーチャム・コーポレイション 化合物
BRPI0710110A2 (pt) * 2006-03-31 2011-08-02 Novartis Ag compostos orgánicos
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
CA2722923C (en) * 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
NZ591115A (en) * 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists

Also Published As

Publication number Publication date
EA201200820A1 (ru) 2013-01-30
US20110137042A1 (en) 2011-06-09
CA2782384A1 (en) 2011-06-16
MX2012006524A (es) 2012-07-17
TW201144282A (en) 2011-12-16
WO2011071730A1 (en) 2011-06-16
JP2013512954A (ja) 2013-04-18
IL219274A0 (en) 2012-06-28
CN102596908A (zh) 2012-07-18
KR20120101667A (ko) 2012-09-14
AR079324A1 (es) 2012-01-18
AU2010328480A1 (en) 2012-05-17
EP2509952A1 (en) 2012-10-17
CL2012001300A1 (es) 2012-09-07
IN2012DN05081A (pt) 2015-10-09

Similar Documents

Publication Publication Date Title
UY33256A (es) Procedimiento de sintesis de derivados de cetobenzofurano
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
MX350892B (es) Síntesis de compuesto antiviral.
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
JO2816B1 (en) A new process for the installation of agililatine
ME00928B (me) Novi postupak za sintezu agomelatina
BR112013001245A2 (pt) método de produção de ingenol-3-angelato
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
NZ586187A (en) Processes for the synthesis of sinomenine derivatives and their intermediate
SV2009003153A (es) Bencilaminas, un proceso para su produccion y su uso como agentes antiinflamatorios
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
IN2014DN00144A (pt)
UY31577A1 (es) Proceso para la preparacion de 6-sustituido-1-(2h)-isoquinolinonas
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]